Swiss Spinal Tumor Registry (Swiss-STR)
Launched by LUZERNER KANTONSSPITAL · Mar 5, 2025
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
The Swiss Spinal Tumor Registry (Swiss-STR) is a study that aims to gather information about patients who have spinal tumors and are undergoing surgery for treatment. This registry collects important data from people who have either primary tumors (those that started in the spine) or metastatic tumors (those that have spread to the spine from another part of the body). The goal is to better understand how these surgeries can help patients and improve their care.
To be part of this trial, patients need to be 18 years or older and have a diagnosis of either a primary or secondary spinal tumor that requires surgery. The study is currently looking for participants, and it welcomes individuals of all genders. Participants can expect to share their medical information and experiences related to their treatment, which will help doctors learn more about spinal tumors and their surgical options. It’s important to know that patients who decide not to proceed with the surgery or withdraw their consent will not be included in the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of primary spinal tumor
- • Diagnosis of secondary (metastatic) spinal tumor
- • Indication for surgical treatment is present
- • Patient age: =/\>18 years
- Exclusion criteria:
- • Withdrawal of consent
- • Withdrawal from initially planned surgical procedure
- • Patient age: \<18 years
About Luzerner Kantonsspital
Luzerner Kantonsspital (LUKS) is a leading academic hospital located in Lucerne, Switzerland, dedicated to providing high-quality healthcare and advancing medical research. As a prominent clinical trial sponsor, LUKS is committed to fostering innovation in medical treatments and therapies through rigorous clinical studies. The institution emphasizes collaboration with multidisciplinary teams of healthcare professionals, researchers, and academic partners to ensure that its trials adhere to the highest ethical standards and regulatory requirements. With a focus on improving patient outcomes, LUKS leverages its state-of-the-art facilities and expertise to contribute significantly to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lucerne, , Switzerland
Patients applied
Trial Officials
Edin Nevzati, MD
Principal Investigator
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported